White Diamond Research · research-note
Accelerate Diagnostics (AXDX)
41 pages · 3 arc beats · 3 loops
Accelerate Diagnostics (AXDX)
White Diamond Research · 2019-09 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
124681012141618202224262830323436384041
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 25 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 7 slides 100% 7/7 slides 100% 7/7 slides · 56 hits — 0/7 slides
— 0/7 slides
28.6% 2/7 slides 100% 7/7 slides 71.4% 5/7 slides Agitate (Make it worse) 6 slides 100% 6/6 slides 83.3% 5/6 slides · 34 hits — 0/6 slides
33.3% 2/6 slides 50% 3/6 slides 100% 6/6 slides — 0/6 slides
Solution (Provide relief) 12 slides 100% 12/12 slides 100% 12/12 slides · 82 hits — 0/12 slides
8.3% 1/12 slides 58.3% 7/12 slides 100% 12/12 slides 83.3% 10/12 slides Slide inventory
41 every slide · same image gating as the playbook
02
This is a short-seller research note highlighting discrepancies between market valuation and actual commercial performance.expose_contradiction
03
Includes a highlighted quote from a peer-reviewed article regarding the system's inability to replace standard of care.expose_contradiction
Open slide detailBeat · Problem (Identify pain)
04
The slide presents qualitative evidence from industry representatives to frame AXDX's competitive position as limited by its narrow focus on blood stream infectname_villain
Open slide detailBeat · Problem (Identify pain)
05
The slide uses external citations (FDA approval, peer-reviewed article, ECCMID poster) to build a negative case against the subject technology.name_villain
06
The slide uses a Q&A format to highlight technical and operational weaknesses in the AXDX Pheno system.expose_contradiction
07
The slide uses a combination of technical critique and competitive intelligence (QuantaMatrix interview) to undermine the value proposition of the Pheno system.expose_gap
08
The slide presents qualitative evidence from industry interviews and literature to argue against the economic viability of the Pheno system.name_villain
09
The slide uses a Q&A format to present anecdotal evidence from industry reps and a physician to challenge the market value of rapid diagnostic systems.expose_contradiction
10
The slide uses a rhetorical question to challenge the value proposition of rapid diagnostics in the context of standard sepsis care protocols.preempt_rebuttal
Open slide detailBeat · Agitate (Make it worse)
11
Image file not available at /tmp/legacy-images/dfcef8f28a20/slides/011.jpg; could not inspect.
Open slide detailBeat · Agitate (Make it worse)
12
The slide includes an embedded image of a conference presentation slide showing a diagnostic validity funnel.diagnose_problem
Open slide detailBeat · Agitate (Make it worse)
13
The slide uses a screenshot of a company presentation to frame a contradiction, then provides a textual rebuttal based on study methodology.expose_contradiction
Open slide detailBeat · Agitate (Make it worse)
14
The slide uses a timeline diagram to illustrate the reduction in time-to-result for blood culture testing.analyze_data
Open slide detailBeat · Agitate (Make it worse)
15
The slide uses a timeline diagram and a comparison table to challenge AXDX's claimed 75% time advantage.compare_peers
Open slide detailBeat · Agitate (Make it worse)
16
The slide uses quotes from management (Reichling, Mehren) to demonstrate a deterioration in business metrics over time, specifically comparing Q2 2018 and Q2 20expose_contradiction
17
The slide explains the methodology for deriving average instrument revenue percentages from disparate analyst reports.analyze_data
18
The table reconstructs cumulative totals based on the provided bar chart data.analyze_data
19
The slide explains the logic behind calculating 'functional system-months' based on contract timing and provides a supporting data table.analyze_data
20
The slide contains two tables: one showing quarterly data points and another showing column headers for a larger dataset.analyze_data
21
The slide uses a data table to expose a discrepancy between management's claims and the analyst's model.analyze_data
22
The chart shows a clear downward trend in reagent revenue per system from Q4 2017 to Q2 2019.expose_contradiction
23
Includes a Q&A excerpt from an investor relations call highlighting the lack of binding minimum test requirements.expose_contradiction
24
The slide contains a series of Q&A exchanges followed by a concluding synthesis paragraph.summarize
25
The slide uses a bearish investment research tone, highlighting risks to the company's business model and clinical validation.diagnose_problem
26
This is a short-seller research note analyzing the timeline of a clinical study and management's subsequent actions.expose_contradiction
27
The slide contrasts optimistic management commentary from 2018 with a more cautious tone in 2019.expose_contradiction
28
The slide uses a quote-based analysis to question the credibility of management's focus on 'time to optimal therapy' over 'mortality and length of stay'.expose_contradiction
29
Image file not available at /tmp/legacy-images/dfcef8f28a20/slides/029.jpg; could not inspect.
30
Includes a direct quote from Lawrence Mehren (CEO) to support the argument.preempt_rebuttal
Open slide detailBeat · Solution (Provide relief)
31
The slide uses a skeptical tone to challenge management's guidance, citing specific quarterly placement figures (133, 75, 55) to highlight a downward trend.diagnose_problem
32
The text highlights a contradiction between management's narrative of 'better pricing' strategy and the observed low compliance in clinical studies.expose_contradiction
33
The slide contrasts positive clinical trial data (PHENOMENON study) with negative market sentiment from a sell-side analyst survey.expose_contradiction
34
The slide presents a bearish thesis on AXDX based on primary research (lab surveys) and reimbursement analysis.diagnose_problem
35
Includes a transcript excerpt from a Q2 2019 earnings call regarding NTAP program applications.compare_peers
36
The table compares T2 Biosystems (implied) vs Accelerate Diagnostics (AXDX).compare_peers
37
The slide uses a narrative-driven argument to discredit the 'insider buying' signal often used by retail investors.preempt_rebuttal
38
The slide uses a table to list holdings and concludes with a negative recommendation based on historical performance.name_villain
39
The slide uses a narrative of corporate governance and executive hierarchy to predict a 'reset' of market guidance.expose_contradiction
40
Research note by White Diamond Research, page 40.diagnose_problem